Jp. Vella et al., INDIRECT ALLORECOGNITION OF MAJOR HISTOCOMPATIBILITY COMPLEX ALLOPEPTIDES IN HUMAN RENAL-TRANSPLANT RECIPIENTS WITH CHRONIC GRAFT DYSFUNCTION, Transplantation, 64(6), 1997, pp. 795-800
Background, It has been suggested that T cells primed by processed don
or major histocompatibility complex antigen (the ''indirect'' pathway
of allorecognition) may be responsible for mediating chronic allograft
rejection. The purpose of this study was to develop a clinically usef
ul assay to study the occurrence of indirect allorecognition during ch
ronic rejection in humans. Methods. A panel of 20 mer peptides corresp
onding to the hypervariable regions of HLA-DRB10101, DRB1*1501, and D
RB10301 were synthesized. Lymphocytes obtained from renal allograft r
ecipients were cocultured with these peptides. Proliferation was assay
ed by DNA incorporation of [H-3]thymidine, and positive proliferation
was defined by a statistically significant increase in counts per minu
te over background with a minimum stimulation index of 2, The precurso
r frequency of allopeptide reactive T cells was determined by limiting
dilution analysis. Results. Lymphocytes from 82% of patients who were
mismatched for at least one of the three DR molecules and had chronic
allograft dysfunction specifically proliferated to the mismatched all
opeptides (n=11), Proliferation was seen in only 6% of control subject
s (2/33, P<0.0001). The proliferative response was low grade and was b
est detected on day 7-8 of culture in vitro. The precursor frequency o
f peptide-specific T cells was more than 10-fold higher compared with
controls (P<0.001). Conclusions. These data demonstrate for the first
time that T cells of patients with chronic graft dysfunction are prime
d to recognize and respond to specific donor-derived major histocompat
ibility complex allopeptides. Our results support the hypothesis that
T cells primed via the indirect pathway of allorecognition may be impo
rtant mediators of chronic rejection and provide the rationale to deve
lop specific therapeutic strategies to prevent or interrupt this proce
ss.